PedAM

Pediatric Disease Annotations & Medicines

Disease	cardiomyopathy
Phenotype	C0011860\|type 2 diabetes
Sentences	9
PubMedID- 20467928	This review focuses on the mechanistic approach to understand the molecular basis of diabetic cardiomyopathy in patients with type 2 diabetes mellitus.
PubMedID- 21283592	Our findings indicate that hyperglycemia is a causal factor for increased levels of pro-inflammatory cytokine mif which plays a role in the development of cardiomyopathy occurring in patients with type 2 diabetes.
PubMedID- PMC4328436	These imaging markers show promise for the detection of pre-clinical cardiomyopathy in patients with type 2 diabetes.
PubMedID- 22166644	Effects of valsartan on diabetic cardiomyopathy in rats with type 2 diabetes mellitus.
PubMedID- 20414371	To date, the mcp-1 –2518 a>g polymorphism has been associated with coronary artery disease, nonfamilial idiopathic dilated cardiomyopathy, carotid atherosclerosis in patients with type 2 diabetes, myocardial infarction, ischemic heart disease, and hypertension [33–38].
PubMedID- 21030723	Atherosclerosis and cardiomyopathy in type 2 diabetes are caused in part by pathway-selective insulin resistance, which increases mitochondrial ros production from free fatty acids and by inactivation of antiatherosclerosis enzymes by ros.
PubMedID- 24389129	Ang 1-7 represents a promising therapy for diabetic cardiomyopathy associated with type 2 diabetes mellitus.
PubMedID- 26317014	Atherosclerosis and cardiomyopathy in type 2 diabetes are caused in part by pathway-selective insulin resistance, which increases mitochondrial ros production from free fatty acids, and by inactivation of antiatherosclerosis enzymes by ros.
PubMedID- 23835259	Although we did not measure the structural or hemodynamic effects of the exercise protocol in db hearts, previous work has shown that the db heart shows similar cardiomyopathy to humans with type 2 diabetes[68,69], which are improved by exercise[13,14].

Page: 1